Determination of the Relative Bioavailability of ARQ 197 Tablet Formulation With Capsule C Formulation as a Reference in Subjects With Advanced Solid Tumors

Inclusion Criteria: * Subjects must have a histologically or cytologically confirmed advanced solid tumor at screening. * Male or female equal or greater than 18 years of age. * All female subjects of childbearing potential must each have a negative serum pregnancy test result before initiating study treatment. * An Eastern Cooperative Oncology Group (ECOG) performance status equal or less than 2 * Adequate bone marrow, liver, and renal function, defined as: * Platelet count equal or greater than 75 x 10(9)/L * Hemoglobin (Hb) equal or greater than 9.0 g/dL * Absolute neutrophil count (ANC) equal or greater than 1.5 x 10(9)/L * Total bilirubin equal or less than 1.5 x upper limit of normal (ULN) * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) equal or less than 3 x ULN (equal or less than 5 x ULN for subjects with liver metastases) * Serum creatinine equal or less than 1.5 x ULN Exclusion Criteria: * History of cardiac disease: Active coronary artery disease (CAD), defined as myocardial infarction (MI), unstable angina, coronary bypass graft (CABG), or stenting within 6 months prior to study entry (an MI that occurred \> 6 months prior to study entry is permitted) * Evidence of uncontrolled bradycardia or other cardiac arrhythmia defined as equal or greater than Grade 2 according to NCI CTCAE, version 4.0, or uncontrolled hypertension * Active, clinically serious infection(s) defined as equal or greater than Grade 2 according to NCI CTCAE, version 4.0. * Known metastatic brain or meningeal tumors, unless the subject is \> 3 months from definitive therapy and clinically stable (supportive therapy with steroids or anticonvulsant medications is allowed) with respect to the tumor at the time of first dose of study drug. * Prior therapy with mesenchymal-epithelial transition factor (c-MET) inhibitors, including ARQ 197.